Anaplastic lymphoma kinase in human cancer

Christina Schoenherr, Bengt Hallberg, Ruth Palmer

Research output: Contribution to journalLiterature reviewpeer-review


The anaplastic lymphoma kinase (ALK) receptor tyrosine kinase is now implicated in a wide range of human cancers. Results from recent clinical trials with ALK inhibitors provide promise for patients harboring oncogenic ALK lesions. This review will discuss our current understanding of ALK in human cancer and the implication of recent results for treatment.

Original languageEnglish
Pages (from-to)123-43
Number of pages21
JournalCritical Review in Oncogenesis
Issue number2
Publication statusPublished - 2012


  • Humans
  • Mutation
  • Neoplasms
  • Protein Kinase Inhibitors
  • Receptor Protein-Tyrosine Kinases


Dive into the research topics of 'Anaplastic lymphoma kinase in human cancer'. Together they form a unique fingerprint.

Cite this